Invention Grant
- Patent Title: Anti-Siglec antibody, pharmaceutical composition comprising the same, and uses thereof
-
Application No.: US17266092Application Date: 2018-09-25
-
Publication No.: US12103969B2Publication Date: 2024-10-01
- Inventor: Shie-Liang Hsieh , Tsung-Yu Tsai , An-Suei Yang , Chung-Ming Yu , Cheng-Yuan Peng
- Applicant: Academia Sinica
- Applicant Address: TW Taipei
- Assignee: Academia Sinica
- Current Assignee: Academia Sinica
- Current Assignee Address: TW Taipei
- Agency: NZ CARR LAW OFFICE
- International Application: PCT/US2018/052759 2018.09.25
- International Announcement: WO2020/068058A 2020.04.02
- Date entered country: 2021-02-04
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P25/28 ; A61P31/20 ; A61K39/00
Abstract:
Disclosed herein is a novel monoclonal antibody exhibiting binding affinity to Siglec-3 receptor. According to the embodiment, the monoclonal antibody is capable of reversing HBV-induced immunosuppression. Accordingly, also disclosed herein are the uses thereof in the treatment and/or prophylaxis of hepatitis B virus (HBV) infection.
Public/Granted literature
- US20210292413A1 ANTI-SIGLEC ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USES THEREOF Public/Granted day:2021-09-23
Information query
